Opinion|Videos|September 30, 2024
Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
The expert panel analyzes strategies for overcoming barriers to prescribing first-line medications for cardiometabolic conditions.
Advertisement
Video content above is prompted by the following:
- Despite being approved for first-line treatment, medications such as SGLT2 inhibitors and GLP1-receptor agonists are not frequently prescribed to qualified patients. What has been effective in your practice to get these first line medications covered in the patient population who needs it the most?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of Myeloma
September 17th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Metabolic Issues More Common in Patients With HIV
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Iron Dysregulation Linked to MS Progression, Review Finds
4
Efficacy of Ruxolitinib Cream in Nonsegmental Vitiligo Confirmed in Real-World Study
5